@article{d6d896a579dd46d6bfabfb15445c2090,
title = "Precise and Programmable Detection of Mutations Using Ultraspecific Riboregulators",
abstract = "The ability to identify single-nucleotide mutations is critical for probing cell biology and for precise detection of disease. However, the small differences in hybridization energy provided by single-base changes makes identification of these mutations challenging in living cells and complex reaction environments. Here, we report a class of de novo-designed prokaryotic riboregulators that provide ultraspecific RNA detection capabilities in vivo and in cell-free transcription-translation reactions. These single-nucleotide-specific programmable riboregulators (SNIPRs) provide over 100-fold differences in gene expression in response to target RNAs differing by a single nucleotide in E. coli and resolve single epitranscriptomic marks in vitro. By exploiting the programmable SNIPR design, we implement an automated design algorithm to develop riboregulators for a range of mutations associated with cancer, drug resistance, and genetic disorders. Integrating SNIPRs with portable paper-based cell-free reactions enables convenient isothermal detection of cancer-associated mutations from clinical samples and identification of Zika strains through unambiguous colorimetric reactions.",
keywords = "colorimetric, diagnostic, isothermal, mutation, paper-based assay, riboregulator, specificity",
author = "Fan Hong and Duo Ma and Kaiyue Wu and Mina, {Lida A.} and Luiten, {Rebecca C.} and Yan Liu and Hao Yan and Green, {Alexander A.}",
note = "Funding Information: This work was supported by funds to A.A.G. from an NIH Director's New Innovator Award (1DP2GM126892), the Gates Foundation (OPP1160667), an Arizona Biomedical Research Commission New Investigator Award (ADHS16-162400), an Alfred P. Sloan Fellowship (FG-2017-9108), Gordon and Betty Moore Foundation (6984), NIH (1R21AI136571), a DARPA Young Faculty Award (D17AP00026), and Arizona State University. The views, opinions, and/or findings contained in this article are those of the authors and should not be interpreted as representing the official views or policies, either expressed or implied, of the NIH, DARPA, or the Department of Defense. F.H. and A.A.G. conceived and designed the study. F.H. D.M. and K.W. conducted the experiments. F.H. performed the data analysis. L.A.M. and R.C.L. acquired the BRCA2 clinical samples and edited the manuscript. Y.L. H.Y. and A.A.G. supervised the study. F.H. and A.A.G. wrote and edited the manuscript. F.H. A.A.G. and H.Y. have filed patent applications related to this work, including F.H. and A.A.G. on international patent application PCT/US2017/044810 filed on August 1, 2017 and F.H. A.A.G. and H.Y. on international patent application PCT/US2017/061796 filed on November 15, 2017. Funding Information: This work was supported by funds to A.A.G. from an NIH Director{\textquoteright}s New Innovator Award ( 1DP2GM126892 ), the Gates Foundation ( OPP1160667 ), an Arizona Biomedical Research Commission New Investigator Award ( ADHS16-162400 ), an Alfred P. Sloan Fellowship ( FG-2017-9108 ), Gordon and Betty Moore Foundation ( 6984 ), NIH ( 1R21AI136571 ), a DARPA Young Faculty Award ( D17AP00026 ), and Arizona State University . The views, opinions, and/or findings contained in this article are those of the authors and should not be interpreted as representing the official views or policies, either expressed or implied, of the NIH, DARPA, or the Department of Defense. Publisher Copyright: {\textcopyright} 2020 The Author(s)",
year = "2020",
month = mar,
day = "5",
doi = "10.1016/j.cell.2020.02.011",
language = "English (US)",
volume = "180",
pages = "1018--1032.e16",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "5",
}